Micalcet (Cinacalcet Hydrochloride)

Cinacalcet binds to the calcium‑sensing receptor on parathyroid cells and increases its sensitivity to extracellular calcium. This heightened sensitivity suppresses parathyroid hormone secretion, which in turn reduces calcium release from bone, renal reabsorption of calcium, and activation of vitamin D, leading to lower blood calcium concentrations.

The exact dose of Micalcet is individualized by the prescribing clinician based on the patient’s serum calcium, phosphorus, and parathyroid hormone levels, as well as renal function and concomitant therapies. Dose adjustments are made during treatment to maintain target laboratory values while minimizing adverse effects.

Safety of cinacalcet during pregnancy and lactation has not been established. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional after careful assessment.

To request Micalcet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to oral cinacalcet is etelcalcetide, an injectable calcimimetic used in dialysis patients. Etelcalcetide is administered intravenously after each dialysis session, whereas cinacalcet is taken orally, offering greater convenience but requiring daily adherence. Both share a similar mechanism of calcium‑sensing‑receptor activation.

Micalcet tablets should be stored at room temperature, below 25 °C, in their original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required.

Micalcet is taken by mouth, usually with a glass of water. The tablet should be swallowed whole and not split or crushed unless specifically instructed by a healthcare professional. Administration timing (e.g., with or without food) follows the prescriber’s guidance.

The most serious risks include severe hypocalcemia, which can cause seizures, cardiac arrhythmias, or muscle tetany, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be educated to report symptoms like muscle cramps, tingling, or unexplained rashes promptly.

Micalcet should be avoided in individuals with known hypersensitivity to cinacalcet or any of its excipients. Caution is also advised for patients with uncontrolled cardiac arrhythmias, severe liver disease, or those who are pregnant or breastfeeding unless the benefits clearly outweigh the risks.